AP3 Rec'd PCT/PTO 11 MAY 2005

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 700953-53666 DESIGNATED/ELECTED OFFICE (DO/EO/US) PPLICATION NO. (If known, see 37 CFR 1.5) 7 Ober assigned **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. 12 November 2003 (12.11.2003) 12 November 2004 (12.11.2004) PCT/US2004/037810 TITLE OF INVENTION SYSTEM FOR TREATING AND PREVENTING BREAST CANCER APPLICANT(S) FOR DO/EO/US Therion Biologics Corporation, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) Xis attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. [X] is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary-Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 11. X An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13 X A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 17. X A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IAP20Rec'd PCT/PTO 11 MAY 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ICATION NO. (#knews sep 37 CPRs).5)
INTERNATIONAL APPLICATION NO.

U.S. APPLICAT	ton No. (#knews) Bute assigne	See 37 GPR (1.5)	PCT/US2004		700953-53	ľ	
20. Other items or information: Exp. Mail Cert. EV653005037US; COPY-Cert. of Limited Recognition; ORIGINAL-Statement Accompanying Seq. Listing; ORIGINAL-Seq. Listing; ORIGINAL-CRF; Statement Accompanying Substitute Seq. Listing; PAPER COPY-Substitute Seq. Listing; Substitute-CRF; COPY-Assignment from Parent; COPY-Int'l Search Report; COPY-References B1 and C1-C6 and Return Receipt Postcard.							
The follo	owing fees have be	een submitted			CALCULATIONS	PTO USE ONLY	
				\$300	\$ 300.00		
If the written opin	nination fee (37 CF nion prepared by IS US indicates all cla ns	\$ 200.00					
If the written opin IPEA/US Search fee (37 C International Sea	rch fee (37 CFR 1. iion of the ISA/US i indicates all claim FR 1.445(a)(2)) had onal Searching Autrich Report preparty y communicated to	\$ 100.00	·				
All other situations					600.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Total Sheets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole number)							
99 - 100 =				x \$250	\$ 0.00 ¹		
Surcharge of \$13	30.00 for furnishing commencement of	\$ 130.00					
CLAIMS NUMBER		ER FILED	NUMBER EXTRA	RATE	\$		
Total claims	43	- 20 =	23	x \$ 50	\$ 1,150.00		
Independent clai	ms 8	- 3 =	5	x \$200	\$ 1,000.00		
MULTIPLE DEP	ENDENT CLAIM(S	S) (if applicable)	TOTAL OF ABOVE	+ \$360	\$ 0.00		
		\$ 2,880.00					
Applicant cla	aims small entity s	tatus. See 37 CFF	R 1.27. Fees above are reduc		0.00		
_				SUBTOTAL =	\$ 2,880.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$	0.00	
			TOTAL	NATIONAL FEE =	\$	2,880.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property					\$	0.00	
TOTAL FEES ENCLOSED =					\$	2,880.00	
				 	Amount to be refunded:	\$	
	 	···	· · · · · · · · · · · · · · · · · · ·		Amount to be charged	\$	

10/579007

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	·								
a. A che	eck in the amount of \$	AP20 Rec'd PCT/PTO 11 MAY 2006 to cover the above fees is enclosed.							
b. X Pleas	se charge my Deposit Account No. 50-0850 plicate copy of this sheet is enclosed.	in the amount of \$ $2,880.00$ to cover the above fees.							
c. X The C	commissioner is hereby authorized to charge any unt No50-0850 A duplicate copy of this she	additional fees which may be required, or credit any overpayment to Deposit eet is enclosed.							
d. Fees be in	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CO Ronald I. E Nixon Peal 100 Summ Boston, MA	body LLP er Street	SIGNATURE Ronald I. Eisenstein/Leena H. Karttunen NAME 30,628 REGISTRATION NUMBER							

!AP20 Rec'd PCT/PTO 11 MAY 2006

Practitioner's Docket No. 700953-53666

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date	
PCT/US2004/037810	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)	

TITLE OF INVENTION:

SYSTEM FOR TREATING AND PREVENTING BREAST

CANCER

APPLICANT FOR DO/US:

THERION BIOLOGICS CORPORATION, et al.

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE (INTERNATIONAL APPLICATION (37 C.F.R. section 1.10(c))

I declare that, on May 11, 2006 I deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number EV653005037US, addressed to the "MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450," and having an express mail certification that I executed, the following papers:

- 1. Express Mail Certificate EV653005037US (1 pg.);
- 2. COPY-Certificate of Limited Recognition (1 pg.);
- 3. Transmittal Letter Under 35 U.S.C. 371 page 3 in duplicate (4 pp.);
- 4. Application Data Sheet (3 pp.);
- 5. Preliminary Amendment (9 pp.) and Appendices (6 pp.);
- 6. ORIGINAL Statement Accompanying Sequence Listing (1 pg.);
- 7. ORIGINAL Sequence Listing (6 pp.);
- 8. ORIGINAL Computer-Readable Form of Sequence Listing (1 diskette);
- 9. Statement Accompanying Substitute Sequence Listing (1 pg.);
- 10. PAPER COPY Substitute Sequence Listing (6 pp.);
- 11. SUBSTITUTE Computer-Readable Form of Sequence Listing (1 diskette);
- 12. COPY Assignment from Parent (7 pp.);
- 13. Information Disclosure Statement, including Form 08a and b (4 pp.);
- 14. International Search Report Form PCT/ISA/210 (5 pp.);
- 15. COPY References B1 and C1-C6 cited in International Search Report; and
- 16. Return Receipt Postcard.

A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own which whedge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Linda M. Ginsberg

(type or print name of person certifying)

Date: May 11, 2006

10/579007

AP20Rec'd PCT/PTO 11 MAY 2006

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Leena H. Karttunen is hereby given limited recognition under 37 CFR §11.9(b) as an employee of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Nixon Peabody LLP and an attorney or agent of record in the applications is a registered practitioner who is a member of Nixon Peabody LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with Nixon Peabody LLP ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. <u>L0207</u> Expires: February 11, 2007

Harry I. Moatz

Director of Enrollment and Discipline